Francesca Chiara Giorgi
A5016688954- Cancer Immunotherapy and Biomarkers
- Diabetes Treatment and Management
- Pancreatic and Hepatic Oncology Research
- Neutropenia and Cancer Infections
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Metabolism, Diabetes, and Cancer
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Inflammatory Biomarkers in Disease Prognosis
- Economic and Financial Impacts of Cancer
- Immune cells in cancer
- Gastric Cancer Management and Outcomes
- Renal Transplantation Outcomes and Treatments
- Ferroptosis and cancer prognosis
- Chronic Lymphocytic Leukemia Research
- Advanced Breast Cancer Therapies
- Medication Adherence and Compliance
- Diabetes and associated disorders
- Palliative Care and End-of-Life Issues
- Childhood Cancer Survivors' Quality of Life
- Ethics and Legal Issues in Pediatric Healthcare
- Frailty in Older Adults
- Metastasis and carcinoma case studies
- Cancer Diagnosis and Treatment
- Patient Dignity and Privacy
Abstract Purpose: No evidence exists as to whether type 2 diabetes mellitus (T2DM) impairs clinical outcome from immune checkpoint inhibitors (ICI) in patients with solid tumors. Experimental Design: In a large cohort of ICI recipients treated at 21 institutions June 2014 2020, we studied on glucose-lowering medications (GLM) for T2DM had shorter overall survival (OS) and progression-free (PFS). We used targeted transcriptomics subset explore differences the tumor microenvironment (TME) or...
The favourable safety profile and the increasing confidence with immune checkpoint inhibitors (ICIs) might have boosted their prescription in frail patients short life expectancies, who usually are not treated standard chemotherapy.
Background: FLOT perioperative chemotherapy represents the standard of care in non-metastatic gastric cancer patients. Signet-ring cell positivity is associated with a worse prognosis patients treated chemotherapy. Comparison between vs. surgery followed by adjuvant based on signet-ring lacking. The aim analysis was to compare stratified positivity. Methods: We conducted retrospective multicenter disease-free survival (DFS) and overall (OS) who received regimen compared their historical...
<p>Tumour micron-environment transcriptome analysis.</p>
Hope is a strange invention – A Patent of the Heart In unremitting action Yet never wearing out —Emily Dickinson It was an ordinary Monday morning at outpatient oncology clinic. As usual, it busy day; waiting room crowded with patients lining up for examinations, laboratory tests, and chemotherapy sessions. Telephone calls about myriad problems that had occurred over weekend, requiring unscheduled visits to clinic, seemed end. Late in morning, colleague from gynecology called me. “My sister...
<p>Kaplan-Meier survival estimates according to the receipt of no diabetes medication, other medications/insulin therapy only, and metformin (either alone or in combinations). A) Overall Survival whole cohort; patients not receiving medications: 18.9 months (95%CI: 15.9-21.6; 684 events), on only: 19.3 11.6-22.9; 48 metformin: 12.3 9.8-15.9; 100 events). B) Progression Free 8.2 7.1-9.4; 872 10.7 6.7-11.6; 61 7.9 5.1-10.1; 124 events).</p>
<p>Kaplan-Meier survival estimates according to the receipt of other diabetes medications and insulin therapy. A) Overall Survival whole cohort; patients on oral antidiabetic drugs therapy: 17.5 months (95%CI: 12.8-20.9; 82 events), not receiving therapy 17.8 15.4 – 19.7; 750 events). B) Progression Free 8.2 6.2-11.4; 106 8.1 7.1 9.2; 951 events).</p>
<p>Kaplan-Meier survival estimates according to the receipt of metformin. A) Overall Survival whole cohort; patients on metformin: 12.4 months (95%CI: 10.5-16.3; 100 events), not receiving 19.0 16.4 – 21.1; 732 events). B) Progression Free 7.9 5.3-10.1; 124 8.3 7.3 9.5; 933 events).</p>
<p>Volcano plot of differentially regulated genes identified by Nanostring analysis. The Benjamini–Hockberg P-values are correlated to fold-changes in transcripts diabetic samples (n = 11) versus non-diabetic controls 11). achieving the highest statistical significance (p value <0.05) highlighted presence corresponding gene name. Significantly downregulated transcripts: HRAS, Ras oncogene family (p=0.009); GTF3C1, transcription factor TFIIIC complex (p=0.018); LAG3, key immune...
<p>A) Heat map of the 770 transcripts analyzed with Nanostring Pancancer Immune Panel in diabetic samples (n=11) compared non-diabetic controls (n=11). B) selected differently transcripted genes.</p>
<p>Scatter diagram with regression line summarizing the linear analysis between median baseline glycaemia (used as independent variable: x-axes) and NLR dependent y-axes). 133 patients included; A significant equation was found F(1,131)= 4.09, p = 0.04) an R2 of .030. NLR: neutrophil to lymphocyte ratio.</p>
<div>Abstract<p><b>Purpose:</b> No evidence exists as to whether type 2 diabetes (T2DM) impairs clinical outcome from Immune Checkpoint Inhibitors (ICI) in patients with solid tumors. <b>Experimental Design:</b> In a large cohort of ICI recipients treated at 21 institutions June 2014 2020, we studied on glucose lowering medications (GLM) for T2DM had shorter OS and PFS. We used targeted transcriptomics subset explore differences the tumor microenvironment...
<p>Kaplan-Meier survival estimates according to the receipt of any diabetes medication. A) Overall Survival NSCLC matched cohort; patients on medication: 14.2 months (95%CI: 9.0 – 17.5; 99 events), not receiving medications: 17.5 26.6; 77 events). B) Progression Free 7.9 5.4 10.8; 113 10.1 7.7 13.8; C) Melanoma 22.9 12.0 NR; 25 NR 28.8 52 D) 11.4 4.9 23.4; 37 13.8 8.7 26.0; NR: reached; PSM: propensity score matching.</p>
<p>A) Heat map of the 770 transcripts analyzed with Nanostring Pancancer Immune Panel in diabetic samples (n=11) compared non-diabetic controls (n=11). B) selected differently transcripted genes.</p>